drug_type
RELEVANT_DRUG
intervention_type
oncolytic viral immunotherapy
drug_description
Peptide-coated, conditionally replicating oncolytic adenovirus administered intratumorally (± subcutaneously) to induce tumor cell lysis and in situ vaccination by enhancing dendritic cell uptake and cross-priming of NY-ESO-1/MAGE-A3–specific CD8+ T cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Oncolytic Viruses
drug_category
ONCOLYTIC VIRUS
drug_class
Gene therapy
drug_delivery_route
Intratumoral, Subcutaneous
drug_mechanism_of_action
PeptiCRAd-1 is a peptide-coated, conditionally replicating oncolytic adenovirus that selectively infects and replicates in tumor cells, causing oncolysis and release of danger signals and tumor antigens. The NY-ESO-1/MAGE-A3 peptide coating enhances dendritic cell uptake and cross-priming, driving NY-ESO-1/MAGE-A3–specific CD8+ T-cell responses. Administered intratumorally (± subcutaneously), it functions as an in situ vaccine to boost antitumor immunity.
drug_name
PeptiCRAd-1
nct_id_drug_ref
NCT05492682